COVID-19 vaccine-makers have been updating their shots to better match omicron in case global health authorities decide the change is needed.
The original vaccines still offer good protection against severe illness and death. Studies in the U.S. and elsewhere have made clear that adding a booster dose strengthens that protection and improves the chances of avoiding even a milder infection. The new U.S. study will include up to 1,420 volunteers ages 18 to 55 to test the updated omicron-based shots for use as a booster or for primary vaccinations. Researchers will examine the tweaked vaccine’s safety and how it revs up the immune system in comparison to the original shots.
Pfizer’s CEO told CNBC earlier this month that the company could have some omicron-matched doses ready as early as March. But doing what the company calls “at-risk” manufacturing doesn’t mean those doses will be rolled out to the public. Pfizer and other vaccine makers also have brewed and tested experimental doses to match previous variants, changes that ultimately weren’t needed but offered valuable practice at tweaking the recipe.
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔
ذریعہ: 92newschannel - 🏆 21. / 51 مزید پڑھ »
ذریعہ: 92newschannel - 🏆 21. / 51 مزید پڑھ »
ذریعہ: Aaj_Urdu - 🏆 8. / 63 مزید پڑھ »
ذریعہ: Aaj_Urdu - 🏆 8. / 63 مزید پڑھ »
ذریعہ: DunyaNews - 🏆 1. / 83 مزید پڑھ »
ذریعہ: 92newschannel - 🏆 21. / 51 مزید پڑھ »